Meeting
2022 ASCO Annual Meeting
Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.
Authors
Eric Jonasch
The University of Texas MD Anderson Cancer Center, Houston, TX
Eric Jonasch , Todd Michael Bauer , Kyriakos P. Papadopoulos , Elizabeth R. Plimack , Jaime R. Merchan , David F. McDermott , M. Dror Michaelson , Leonard Joseph Appleman , Ananya Roy , Yanfang Liu , Rodolfo F. Perini , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02974738
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4509)
DOI
10.1200/JCO.2022.40.16_suppl.4509
Abstract #
4509
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma.
First Author: David F. McDermott
Poster
2022 ASCO Annual Meeting
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2023 ASCO Annual Meeting
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).
First Author: David F. McDermott